Based on these and similar data that showed systemic side effects with anti-TGFβ therapy, a more specific inhibition of TGFβ signaling and a better selection of suitable patient subgroups have been proposed for the treatment of CRC. Here, TGFB1 is linked to colorectal carcinoma.